Good article in the Journal of the Neurological Sciences June 16, 2020 In this systematic review, we will discuss the evidence on the occurrence of
Contact Information
All organizations should report incidents and anomalous activity to CISA 24/7 Operations Center at report@cisa.gov or (888) 282-0870 and/or to the FBI via your local FBI field office or the FBI’s 24/7 CyWatch at (855) 292-3937 or CyWatch@fbi.gov. When available, please include the following information regarding the incident: date, time, and location of the incident; type of activity; number of people affected; type of equipment used for the activity; the name of the submitting company or organization; and a designated point of contact. For NSA client requirements or general cybersecurity inquiries, contact the Cybersecurity Requirements Center at 410-854-4200 or Cybersecurity_Requests@nsa.gov.
CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease Decision Follows Robust Stakeholder Input and Creates Pathway
CMS Returning to Certain Pre-COVID-19 Policies in Long-term Care and Other Facilities Actions continue to protect the health and safety of nursing home residents The
As of April 5, 2022, the U.S. Food and Drug Administration (FDA) reissued the emergency use authorization (EUA) for GSK-Vir Biotechnology’s sotrovimab monoclonal antibody treatment.
“Moral injury has been defined as the “psychological, biological, spiritual, behavioral and social impact of perpetrating, failing to prevent, or bearing witness to acts that